Capsule Summary Slidesets

Share

Program Content

Activities

  • VK2809 in NAFLD
    Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 22, 2019

    Expires: April 20, 2020

Provided by

ProCE Banner

Supporters

AbbVie

Gilead